{"entity":{"id":"crg-150","kind":"drug","name":"CRG-150","aka":["SRC-3KO Treg"],"tldr":"CRG-150 is an experimental autologous gene-edited regulatory T-cell therapy from CoRegen, in phase 1 trials for relapsed or refractory HR-positive HER2-negative breast cancer, triple-negative breast cancer and prostate cancer.","summary":"CRG-150 (SRC-3KO Treg) is an autologous gene-edited regulatory T-cell therapy (Treg) from CoRegen, with Baylor College of Medicine as partner. A patient's own regulatory T cells with the SRC-3 gene disrupted, given back as adoptive cell therapy. Its furthest stage is phase 1, for relapsed or refractory HR-positive HER2-negative breast cancer, triple-negative breast cancer and prostate cancer. ClinicalTrials.gov registers it in one study linked below. FDA notified the company in June 2026 that the CRG-150 study may proceed; phase 1/2 NCT07730125 not yet recruiting, start listed as November 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"CoRegen: coregen.com","url":"https://www.coregen.com/"},{"label":"CoRegen: coregen.com","url":"https://www.coregen.com/pipeline"},{"label":"CoRegen: coregen.com","url":"https://www.coregen.com/pipeline"},{"label":"CoRegen: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07730125"},{"label":"ClinicalTrials.gov: trials of CRG-150","url":"https://clinicaltrials.gov/search?intr=CRG-150"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","tnbc","prostate"],"sections":[],"technologies":[],"targets":["ncoa3"],"drugs":[],"companies":["coregen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07730125"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CRG-150","modality":"Autologous gene-edited regulatory T-cell therapy (Treg)","mechanism":"A patient's own regulatory T cells with the SRC-3 gene disrupted, given back as adoptive cell therapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/crg-150/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/"}],"company":[{"id":"coregen","kind":"company","name":"CoRegen","route":"/companies/coregen/"}],"trial":[{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/"}]}}